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Abstract
Background
Population attributable risk percent (PAR%) is an epidemiological tool that provides an esti-
mate of the percent reduction in total disease burden if that disease could be entirely elimi-
nated among a subpopulation. As such, PAR% is used to efficiently target prevention
interventions. Due to significant limitations in currentClostridium difficile Infection (CDI) pre-
vention practices and the development of new approaches to prevent CDI, such as vaccina-
tion, we determined the PAR% for CDI in various subpopulations in the Medicare 5%
random sample.
Methods
This was a retrospective cohort study using the 2009 Medicare 5% random sample. Comor-
bidities, infections, and healthcare exposures during the 12 months prior to CDI were identi-
fied. CDI incidence and PAR%were calculated for each condition/exposure. Easy to
identify subpopulations that could be targeted from prevention interventions were identified
based on PAR%.
Findings
There were 1,465,927 Medicare beneficiaries with 9,401 CDI cases for an incidence of 677/
100,000 persons. Subpopulations representing less than 15% of the entire population and
with a PAR% 30% were identified. These included deficiency anemia (PAR% = 37.9%),
congestive heart failure (PAR% = 30.2%), fluid and electrolyte disorders (PAR% = 29.6%),
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urinary tract infections (PAR% = 40.5%), pneumonia (PAR% = 35.2%), emergent hospitali-
zation (PAR% = 48.5%) and invasive procedures (PAR% = 38.9%). Stratification by age
and hospital exposures indicates hospital exposures are more strongly associated with CDI
than age.
Significance
Small and identifiable subpopulations that account for relatively large proportions of CDI
cases in the elderly were identified. These data can be used to target specific subpopula-
tions for CDI prevention interventions.
Introduction
The incidence and severity of Clostridium difficile infection (CDI) have increased significantly
in the last decade, and it was the most common pathogen causing healthcare-associated infec-
tions in 2011 [1–3]. It is estimated there were 453,000 incident CDI episodes and 29,300 deaths
in the US due to CDI in 2011 [4]. CDI is estimated to result in at least $4.8 billion in excess U.S.
inpatient hospitalization costs [5]. In addition, CDI adds to morbidity, increasing the likeli-
hood of discharge to long term care facilities (vs. home) by 60% and hospital readmission more
than two-fold [6].
Despite increases in CDI burden, our understanding of CDI epidemiology from a popula-
tion perspective remains incomplete. Most studies have focused on the hospital setting and
identifying individual risk factors for CDI [7,8]. However, a population-based approach is typi-
cally used to improve health and prevent disease within a population. One tool used to identify,
and target, populations at risk for a preventable disease is population attributable risk percent
(PAR%) [9]. PAR% provides an estimate of the percent reduction in total disease burden (e.g.
lung cancer) if the incidence of that disease among a subpopulation (e.g. smokers) could be
entirely eliminated. A more comprehensive understanding of CDI epidemiology that defines
both populations at higher risk and the size of those populations is needed to assist clinicians,
researchers, and policy makers to develop the most effective methods for CDI surveillance and
prevention, and focus these efforts on persons most likely to benefit.
Several initiatives to improve our knowledge of CDI epidemiology exist, but none address
the prevalence of exposures from a population perspective needed to optimize CDI prevention.
The Centers for Disease Control and Prevention (CDC) Emerging Infections Program (EIP)
initiated population-based surveillance for CDI in 2009, providing important information on
persons who develop CDI, the settings where CDI onset occurs, and prevalent strains in the
community and hospitals [4]. However, since data are obtained only from CDI cases, it is not
possible to determine the incidence of CDI for different subpopulations [10]. The Healthcare
Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) has been used to cal-
culate national estimates of CDI hospitalizations. The NIS does not link patients stays over
time, resulting in an over-estimation of CDI incidence and prevalence [1,11]. The CareFusion
and Premier Perspective clinical research databases have also been used to study CDI [12,13].
With these datasets only inpatient data are available from a restricted subset of hospitals, limit-
ing their usefulness to determine population characteristics associated with CDI. Private insur-
ance claims databases have also been analyzed. Limitations of these studies include a restricted
geographic area based on the insurance provider coverage and a younger, healthier patient
population at lower risk of CDI [14,15].
CDI PAR%
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Most of these aforementioned approaches have been focused on identifying and quantifying
risk factors for CDI, but the burden of CDI in different subpopulations and the proportion of
CDI cases associated with the different subpopulations have not been clearly established. This
information is needed to optimize surveillance efforts, identify new opportunities for preven-
tion, and to prioritize efficient population-based interventions. Comprehensive data are avail-
able from both the inpatient and outpatient settings in the Medicare 5% random sample, which
allows for the study of CDI at the population level. To improve our understanding of CDI in
the elderly from a population perspective, we conducted a retrospective cohort study using the
Medicare 5% random sample.
Methods
Data Sources and Study Design
The 2009 Medicare 5% random sample (Chronic Condition Warehouse) was used for this
study. Data on inpatient, outpatient, skilled nursing, and Part D outpatient drug data (see SI
File for details) were used. Medicare Part A and Part B fee-for-service coverage from January 1,
2008 through December 31, 2009 (or through death) was required. Approval to conduct this
research was obtained from the Washington University School of Medicine Human Research
Protection Office. A waiver of informed consent was granted. Data were deidentified.
Outcomes and Definitions
CDI case identification. The first episode of CDI was identified for each person in 2009.
Criteria for CDI included any of the following:
1. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnosis code for CDI (008.45) during an inpatient hospital stay;
2. 008.45 ICD-9-CM code in an outpatient encounter (excluding claims with place of service
code, provider type code, or type service code of diagnostic laboratory, or if the only UB-92
revenue center codes were for laboratory services (0300–0309));
3. Outpatient CDI therapy (non-topical metronidazole, oral vancomycin) within 14 days of a
claim for a C. difficile test.
The date of CDI onset was defined as the first date with a coded diagnosis of CDI, unless
additional information was available for an earlier onset based on symptoms or other indica-
tions of CDI (e.g. diagnosis of diarrhea, see S1 File). Every person was assigned an index date.
For persons with CDI, the index date was the date of onset of CDI. For persons without CDI,
an index date was randomly assigned such that the distribution of index dates among persons
without CDI mirrored the distribution of index dates of people with CDI. Definitions for
comorbidities, prior infections, and healthcare exposures are provided in S1 File.
Analyses
The incidence of CDI per 100,000 persons was calculated overall and for all of the comorbidi-
ties, infections and healthcare exposures (the subpopulations or exposures). The relative risk
and PAR% for each subpopulation were calculated using formula two in Rockhill et al[16] as
follows: PAR% = (P(E) x (RR—1))/ ((P(E) x (RR—1)) + 1)
Where P(E) = prevalence of the exposure and RR = relative risk. PAR% is a comparison of
the incidence rate of the outcome (i.e. CDI) in the exposed group (i.e. subpopulation: comor-
bidity, infection, or healthcare exposure) with the incidence in the counterfactual situation in
CDI PAR%
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which the exposure is absent, and gives an estimate of the percent reduction in CDI cases in
the total population if the incidence of CDI among people with the exposure could be entirely
eliminated [17]. CDI incidence and PAR% for each subpopulation were then stratified by time
from the last exposure to the index date (3, 3–6, and 6–12 months, for infection and health-
care exposures only), age (66–70, 71–75, 76–80, 81–85,>85), and hospitalization in the three
months prior to the index date (no hospitalization, non-emergent hospitalization, emergent
hospitalization). SAS version 9.3 (Cary, N.C.) and SPSS version 21 (IBM Statistics, Chicago,
IL.) were used for analyses. This study received approval from the Washington University
Human Research Protection Office.
Results
There were 1,465,927 persons in the Medicare data with a total of 488,344 hospitalizations and
11,385,402 outpatient visits in 2009 (Table 1). The overall incidence of CDI per 100,000 per-
sons was 677. The prevalence of comorbidities, and CDI incidence and PAR% for each comor-
bidity are in Table A in S1 File and Figs 1 and 2. None of the comorbidities in the top three of
CDI incidence (weight loss 4,124/100,000, paralysis 4,011/100,000, blood loss anemia 3,305/
100,000) were in the top three for PAR% because of the relatively low prevalence of these con-
ditions. The comorbidities in the top three for PAR% were hypertension (60.6%), deficiency
anemia (37.9%), and congestive heart failure (30.2%). 793,466 (54.1%) of people had hyperten-
sion. Discarding hypertension, fluid and electrolyte disorder would be in the top three PAR%
(29.6%), and the prevalence of these three comorbidities with a top PAR% would be lower than
13%.
The incidence of CDI and PAR% were also calculated for a variety of infections and health-
care exposures. As more time elapsed between the infections and healthcare exposures exam-
ined and the index date, in general the CDI incidence and PAR% decreased, indicating most
CDI cases occurred within three months of the inciting infection or healthcare exposure
(Table A in S1 File). As a result, the focus of the infection and healthcare exposures were on the
results within three months before the index date. The relative changes over time in CDI inci-
dence and PAR% were lowest for “chronic” health exposures, i.e. outpatient dialysis and nurs-
ing home residence.
The incidence of CDI was highest for several acute infections (Table A in S1 File and Figs 1
and 2). Less than 25% of Medicare beneficiaries had one or more infections within three
months before the index date, but the PAR% for people with at least one infection was 744%.
Table 1. Characteristics of the study population.
Characteristic Number (%)
Population size 1,465,927
Female 897,227 (61.2)
White race 1,266,929 (86.4)
Number of people with  1 hospitalization 279,797 (19.1%)
Total number of hospitalizations 488,344
Number of people with  1 outpatient encounter 1,297,518 (88.5%)
Number of outpatient visits 11,385,402
Number of people with 1 or more episodes of CDI 9,401 (0.64%)
Incidence of CDI/100,000 persons ( 1 episode)* 677
* Person-year exposure was censored for death
doi:10.1371/journal.pone.0146822.t001
CDI PAR%
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Fig 1. CDI incidence and CDI population attributable risk percent (PAR%) of comorbidities (A), infections
within 3 months of CDI (B), and healthcare exposures within 3 months of CDI (C). No NH / No SNF = people
without a nursing home or skilled nursing facility exposure within 3 months of CDI; Yes NH / No
SNF = nursing home residents without a skilled nursing facility exposure within 3 months of CDI; No NH / Yes
SNF = people without a nursing home exposure but with a skilled nursing facility exposure within 3 months of
CDI; Yes NH / Yes SNF = nursing home residents.
doi:10.1371/journal.pone.0146822.g001
Fig 2. Graph of populations size (X-axis) versus CDI incidence (Y-axis) of comorbidities, infections within three months of CDI, and healthcare
exposures within three months of CDI. The size of the circles represents the relative difference in population attributable risk percent (PAR%) for each
exposure examined. (Comorbidities (blue bubbles): ANY COMORB = any comorbiditiy, ARTH = arthritis, BL ANEM = blood loss anemia, CA = solid tumor,
CHF = congestive heart failure, COAG = coagulopathy, COPD = chronic lung disease, DEF ANEM = deficiency anemia, DEP = depression, DIAB = diabetes
mellitus, FED = fluid and electrolyte disorder, HTN = hypertension, HYPOT4 = hypothyroid, LYMPH = lymphoma, MTCA = metastatic cancer, NEUR = other
neurological disorder, OBES = obesity, PARAL = paralysis, PSY = psychoses, PULM CD = pulmonary circulatory disorder, PVD = peripheral vascular
disease, RF = renal failure, VALVE = valvular disease, WT LOSS = weight loss; Infections (red bubbles): ABSC = abscess in organ/meningitis; ANY
INF = any infection, B&J = bone/joint infection, GASTRO = gastroenteritis, GYN = female pelvic infection, INTRA ABD = intra-abdomional abscess/peritonitis,
OM = otitis media, ORAL ABSC = oral abscess, PNA = pneumonia, SEPSIS = clinical sepsis, SEPT = septicemia/endovascular infection, SSI = surgical site
infection, SSTI = skin/soft tissue infection, TONSIL = tonsillitis, URTI = upper respiratory tract infection, UTI = urinary tract infection, VIRAL = viral infection;
Healthcare exposures (green bubbles): DIAL = outpatient dialysis, ED visit = emergency department visit without hospitalization, ELECT HOSP = non-
emergent hospitalization, EMERGHOSP = emergent hospitalization, 2+ HOSP YEAR = at least two hospitalizations in the last year; INV = any invasive
procedure, OUTPT INV, outpatient invasive procedure, SURG = surgery; Yes NH / No SNF = nursing home residents without a skilled nursing facility
exposure within 3 months of CDI; No NH / Yes SNF = people without a nursing home exposure but with a skilled nursing facility exposure within 3 months of
CDIAge (clear bubbles): 66–70 = 66 to 70 years old, 71–75 = 71 to 75 years old, 76–80 = 76 to 80 years old, 81–85 = 81 to 85 years old, 85+ = >85 years old)
doi:10.1371/journal.pone.0146822.g002
CDI PAR%
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Only one infection in the top three for CDI incidence (septicemia 19,710/100,000, clinical sep-
sis 16,825/100,000, and gastroenteritis 13,239/100,000) was in the top three for PAR% (septice-
mia, 24.8%). The other two infections in the top three for PAR% were urinary tract infection
(40.5%) and pneumonia (35.2%). The prevalence of all top three PAR% infections was lower
than 8.0%.
More frequent healthcare exposures and healthcare exposures associated with greater acuity
of illness were associated with a higher CDI incidence. The CDI incidence was higher if the
person had at least two hospitalizations in the past year (4,555/100,000 persons) compared to
one hospitalization (1,561/100,000 persons) (Table A in S1 File, Figs 1 and 2). The CDI inci-
dence was also higher for emergent hospitalizations within the past three months (6,594/
100,000 persons) than for non-emergent hospitalizations (2,989/100,000 persons) and treat-
and-release ED visits (2,840/100,000 persons). The healthcare exposure in the past three
months with the highest CDI incidence was among people living in the community who were
admitted to a skilled nursing facility after a hospitalization (no NH / yes SNF 7,762/100,000),
followed by emergent hospitalization, and surgery (6,172/100,000). The healthcare exposures
in the top three for PAR% were any hospitalization in the last year (70.5%), an emergent hospi-
talization in the past three months (48.5%), and invasive procedure in the past three months
(38.9%).
The CDI incidence by age was lower than the overall CDI incidence for all age groups other
than 81–85 and>85 years old (Fig 2, Table A in SI File). Only the>85 age group had a CDI
incidence greater than any individual comorbidity irrespective of the age. Likewise, the only
infection with a lower CDI incidence than these two age groups was otitis media, and all
healthcare exposures had a higher CDI incidence than all age groups. Stratifying all comorbidi-
ties, infections, and healthcare exposures by age and hospital exposures in the past three
months indicate hospital exposure is a better marker to identify populations at risk for CDI
than age, with emergent hospitalization being the key exposures (Figs 3 and 4, Tables B and C
in S1 File). In general, CDI incidence and PAR% increase with increasing age, but the propor-
tional differences in CDI incidence and PAR% for emergent hospitalization versus non-emer-
gent hospitalization and no hospitalization is much greater than between the age categories.
Discussion
The purpose of this study was to develop a more complete understanding of specific subpopu-
lations at risk for CDI. These are essential data needed to design targeted CDI prevention strat-
egies and to develop and assess CDI control policies that may impact CDI risk in the
population. We used an innovative approach to identify target populations for CDI prevention
interventions, focusing not just on the incidence of CDI within certain subpopulations, but
also on the PAR%, which takes into account both the incidence of disease (i.e. CDI) and the
prevalence of exposures/subpopulations (i.e. comorbidities, acute infections, healthcare utiliza-
tion) within the population. PAR% was instrumental in determining the impact of smoking on
lung cancer risk, leading to targeting of prevention efforts to reduce lung cancer by reducing
smoking [18,19]. From the perspective of identifying populations to target for surveillance and
prevention efforts, focus on a combination of high incidence and high PAR% exposures is
likely to be most effective, since surveillance and prevention efforts will be focused not just on
populations most likely to benefit (i.e. high incidence), but also on exposures that account for a
high proportion of CDI cases [19].
Among the many informative findings of this study, the primary one is that markers of
overall debility (i.e. deficiency anemia and fluid and electolyte disorders) and acuity of illness,
in addition to recent infections, are keys to identifying populations at risk for CDI. The CDI
CDI PAR%
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incidence of the comorbidities was relatively modest compared to infections and healthcare
exposures, and none of the comorbidities typically found to have strong associations with CDI
in the hospital setting (e.g. congestive heart failure, cancer, renal failure, chronic lung disease)
were amongst the conditions with the highest CDI incidence [20,21]. Conversely, deficiency
anemia and fluid and electrolyte disorders, indicators of overall debility, were among the
comorbidities with the highest PAR%.
The importance of overall debility and acuity of illness in identification of populations at
higher risk for CDI is further supported by the healthcare exposure and age results. The health-
care exposures with the highest CDI incidence were those associated not only with a recent
hospitalization, but a recent emergent hospitalization. The PAR% for an emergent hospitaliza-
tion within the three months prior to CDI was almost 50%. For all comorbidities and health-
care exposures, the CDI incidence and PAR% were higher for people with a recent emergent
hospitalization compared to a non-emergent hospitalization. This is likely a reflection that peo-
ple with emergent hospitalizations have a high severity of underlying illness due to an acute
condition and often have infections and/or are at increased risk for developing infections. In
contrast, people with non-emergent hospitalizations are typically admitted for elective proce-
dures, and therefore are healthy enough for the elective procedure. Consistent with this, this
trend did not always hold when comparing non-emergent hospitalizations to people who had
no hospitalization, again indicating it is important to take into account the circumstances sur-
rounding the hospitalization when identifying people at high risk for CDI.
At face-value, it may seem counter intuitive that age by itself may not be an ideal marker to
identify populations at risk for CDI among the elderly. A dose-response relationship between
age and CDI incidence and PAR% exists, but this relationship was not as strong as the associa-
tion between CDI and emergent hospitalization or CDI and infection. In this study there were
213,500 people>85 years old, the age category with the highest CDI incidence (1,330/100,000)
and PAR% (18.3%). In comparison, there were 73,779 people with an emergent hospitalization
(6,514/100,000 and 48.5% CDI incidence and PAR%, respectively) and 117,127 people with a
urinary tract infection (3,632/100,000 and 40.5%, respectively). Targeting CDI prevent efforts
to these two groups would prevent more CDI than targeting people greater than 85 years old,
but fewer people would be need to be exposed to the intervention.
The conditions associated with the highest CDI incidence not surprisingly were acute infec-
tions. Six of the infections evaluated had a CDI incidence higher than the healthcare exposure
with the highest CDI incidence (Fig 1, Table A in S1 File). Infections are associated with a high
acuity of illness, and people who are debilitated are at increased risk for infection. In addition,
antimicrobials are used to treat infections, and antimicrobial exposure is indisputably the
greatest risk factor for CDI [22]. The association of CDI with previous gastroenteritis is less
clear. We could not determine from the administrative data alone if the previous episode coded
as gastroenteritis was actually undiagnosed CDI, or if gastroenteritis was due to another cause
and asymptomatic C. difficile colonization was subsequently detected and coded as CDI [23].
Alternatively, some data indicate gastroenteritis due to causes other than C. difficilemay pre-
dispose to CDI [24]. Two infections of particular note from our study are pneumonia and
Fig 3. CDI incidence and CDI population attributable risk percent (PAR%) of comorbidities (A), infections
within 3 months of CDI (B), and healthcare exposures within 3 months of CDI (C) stratified by age.
Comorbidities and infections were limited to those with a top three PAR%. No NH / No SNF = people without
a nursing home or skilled nursing facility exposure within 3 months of CDI; Yes NH / No SNF = nursing home
residents without a skilled nursing facility exposure within 3 months of CDI; No NH / Yes SNF = people
without a nursing home exposure but with a skilled nursing facility exposure within 3 months of CDI; Yes NH /
Yes SNF = nursing home residents.
doi:10.1371/journal.pone.0146822.g003
CDI PAR%
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urinary tract infection. These infections had the highest PAR% (35.2% and 40.5%, respectively)
among acute infections, and are commonly treated with cephalosporins and fluoroquinolones,
antimicrobials associated with the highest risk for CDI [22].
This study utilized the Medicare 5% random sample, an administrative claims database.
Advantages are that the data are collected in a similar fashion and the cohorts are large and
representative of the US population>65 years of age, and use of administrative data to identify
CDI has been validated [25]. Limitations include reliance on coding data without an assess-
ment of the patient’s clinical course. Efforts were made to minimize risk of temporally misclas-
sifying an event that occurred after CDI as an exposure. In addition, the Medicare 5% random
sample lacks data on inpatient antimicrobial exposures, outpatient antimicrobial exposures
among people who do not have part D, and laboratory results and vital signs in all settings.
Availability of antimicrobial exposure and vital sign data would help identify the impact of spe-
cific antimicrobials and acuity of illness on CDI incidence and PAR%. The results of this study
may not be generalizable outside of the US as well.
A major strength of analysis of the Medicare 5% random sample is that these data allowed
for a population-based approach to identify specific subpopulations at high risk for CDI. This
is particularly important as<25% of CDI cases have onset within a hospital [4]. Also, identify-
ing individuals at risk for CDI based on a multitude of risk factors is complex, not always feasi-
ble operationally, and it is not always clear what to do once the individual is identified [26]. A
population based approach allows for focus on easily identifiable characteristics, which can
facilitate implementation of subpopulation-based CDI prevention interventions.
A unique feature of this study was use of PAR% in addition to CDI incidence to identify
subpopulations at risk for CDI. When used in combination, these epidemiological tools can be
leveraged to identify key subpopulations to target interventions. This is demonstrated visually
with Fig 2, where potential desirable target populations can be quickly identified based on the
size of the population (x-axis), incidence of CDI (y-axis), and size of the bubble (PAR%). In
some respects we applied PAR% outside of its traditional context, in which there is a direct
cause and effect relationship between the exposure and outcome being examined (e.g. smoking
and lung cancer). The PAR% represents the anticipated decrease in the outcome if the exposure
were completely removed from the population. Along these lines, the subpopulations were ana-
lyzed without risk adjustment of the PAR% for a subpopulation. The goal of this study was to
determine if there were readily identifiable subpopulations to which prevention efforts could
be targeted. Risk adjustment is not necessary to accomplish this, and would make identification
of subpopulations significantly more complicated.
The broader context we applied to the calculation of PAR% for CDI was done purposefully.
There is a C. difficile vaccine currently in phase III study, with others in development [27].
Although deficiency anemia is unlikely to be in the causal pathway for CDI, it is likely a marker
for people at increased risk for an emergent hospitalization and/or antimicrobial exposure, and
therefore may be a marker to identify populations where there are both individual (high inci-
dence condition) as well as population (high PAR%) benefits to vaccination. Examples of
other high-value targets for vaccination we identified would be emergent hospitalizations,
Fig 4. CDI incidence and CDI population attributable risk percent (PAR%) of comorbidities (A), infections
within 3 months of CDI (B), healthcare exposures within 3 months of CDI (C), and age stratified by hospital
exposures (D) in the three months prior to CDI. Comorbidities and infections were limited to those with a top
three PAR%. No NH / No SNF = people without a nursing home or skilled nursing facility exposure within 3
months of CDI; Yes NH / No SNF = nursing home residents without a skilled nursing facility exposure within 3
months of CDI; No NH / Yes SNF = people without a nursing home exposure but with a skilled nursing facility
exposure within 3 months of CDI; Yes NH / Yes SNF = nursing home residents
doi:10.1371/journal.pone.0146822.g004
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pneumonia, and urinary tract infections. The results of this study can also be used to design
and implement other CDI prevention interventions. Antimicrobials are frequently initiated in
the ED, and the PAR% for treat and release ED visits was 22.3%. Antimicrobial stewardship
programs typically focus on the hospital setting, but including the ED in antimicrobial steward-
ship activities may be beneficial in regards to preventing CDI. The same argument applies to
antimicrobial stewardship programs that target pneumonia and urinary tract infection diagno-
sis and treatment, which could lead to large reductions in CDI incidence in the population
because of the high PAR% for these infections.
Past research has focused on CDI incidence and independent risk factors for CDI. Although
this approach will identify subpopulations at increased CDI risk, it may miss opportunities to
maximize CDI prevention efforts by not taking into account the prevalence of the risk factors.
The PAR% adds to our understanding by identifying specific subpopulations that account for a
large proportion of CDI cases. Attributable risk measures provide a public health dimension to
the appraisal of risks and assist in maximizing the effectiveness of prevention efforts by focus-
ing on not just high risk but highly exposed populations [19,28]. Using the combination of
exposure prevalence, CDI incidence, and PAR%, we found that many populations often con-
sidered targets for CDI prevention account for a relatively low proportion of total CDI cases.
Based on the Medicare data, specific subpopulations that are easily identifiable could be tar-
geted for high-impact, cost-effective CDI prevention interventions. These potential high
impact subpopulations include people with deficiency anemia, congestive heart failure, fluid
and electrolyte disorders, urinary tract infections, pneumonia, emergency department visits (in
particular if it leads to a hospitalization), and/or invasive procedures. Necessary next steps are
to design and implement interventions to prevent CDI based upon targeting these populations.
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